摘要
【摘要】目的：研究唑来膦酸联合化疗的治疗方法对于晚期非小细胞肺癌骨转移的临床疗效。方法：将我院 2018年 7月至 2019年 7月收治的 24例晚期非小细胞肺癌骨转移患者随机分为观察组、对照组两组。观察组 13例，采用唑来膦酸联合化疗的治疗方式进行治疗；对照组组 11例，只采用化疗进行治疗。观察组、对照组两组患者采用的化疗方案相同。结果：观察组疼痛总缓解率 91.0%，对照组有效率 63.6%，治疗组总体疗效优于对照组， P<0.05，两组不良反应相似，无差别。结论：用唑来膦酸联合化疗治疗方法治疗晚期非小细胞肺癌的骨转移，其疗效较好，值得临床上的推广。
【关键词】唑来膦酸；化疗；晚期非小细胞肺癌骨转移
[abstract] Objective: To study the clinical efficacy of zoledronic acid combined with chemotherapy in the treatment of bone metastasis in advanced non-small cell lung cancer (NSCLC). Methods: 24 patients with bone metastases from advanced non-small cell lung cancer admitted to our hospital from July 2018 to July 2019 were randomly divided into observation group and control group. 13 cases in the observation group were treated with zoledronic acid combined with chemotherapy, while 11 cases in the control group were treated only with chemotherapy. The two groups of patients in the observation group and the control group adopted the same chemotherapy regimen. Results: The total pain relief rate of the observation group was 91.0%, and the effective rate of the control group was 63.6%. The overall effect of the treatment group was better than that of the control group (P < 0.05). The adverse reactions of the two groups were similar without difference. Conclusion: Zoledronic acid combined with chemotherapy for bone metastasis of advanced non-small cell lung cancer is effective and worthy of clinical promotion.
出版日期
2019年06月16日（中国期刊网平台首次上网日期，不代表论文的发表时间）
